Current management challenges in HIV: antiretroviral resistance.
Emergence of drug-resistant viral variants is a major reason why HIV-infected patients experience viral rebound during antiretroviral therapy. Although combination antiretroviral therapy substantially inhibits viral replication, replication-competent mutant virus remains. In addition, it is now clear that virologic failure is not necessarily caused by failure of all drugs in a regimen. The use of resistance-testing data can assist in understanding the reasons for failure of antiretroviral therapy. However, there is a need for additional trials to better define the role resistance testing may play in developing management approaches to mitigate or minimize emergence of resistant HIV.
Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts, USA.
Daniel R
DR
Kuritzkes
Brian A
BA
Boyle
Joel E
JE
Gallant
Kathleen E
KE
Squires
Andrew
A
Zolopa
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D005838:Genotype; D006678:HIV / Q000145:classification / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D010349:Patient Compliance
D019380:Anti-HIV Agents